SK284029B6 - Farmaceutická kompozícia na liečenie roztrúsenej sklerózy - Google Patents

Farmaceutická kompozícia na liečenie roztrúsenej sklerózy Download PDF

Info

Publication number
SK284029B6
SK284029B6 SK931-99A SK93199A SK284029B6 SK 284029 B6 SK284029 B6 SK 284029B6 SK 93199 A SK93199 A SK 93199A SK 284029 B6 SK284029 B6 SK 284029B6
Authority
SK
Slovakia
Prior art keywords
copolymer
cells
eae
day
fed
Prior art date
Application number
SK931-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK93199A3 (en
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Original Assignee
Yeda Research And Development Co., Ltd-Company Of Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd-Company Of Israel filed Critical Yeda Research And Development Co., Ltd-Company Of Israel
Publication of SK93199A3 publication Critical patent/SK93199A3/sk
Publication of SK284029B6 publication Critical patent/SK284029B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
SK931-99A 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy SK284029B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
SK93199A3 SK93199A3 (en) 2000-11-07
SK284029B6 true SK284029B6 (sk) 2004-08-03

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
SK931-99A SK284029B6 (sk) 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy

Country Status (19)

Country Link
EP (1) EP0975351B1 (ko)
JP (1) JP4216342B2 (ko)
KR (1) KR20000070058A (ko)
CN (1) CN100528222C (ko)
AT (1) ATE356608T1 (ko)
AU (1) AU737287B2 (ko)
BR (1) BRPI9807076B8 (ko)
CA (1) CA2277365C (ko)
CZ (1) CZ297983B6 (ko)
DE (1) DE69837324T2 (ko)
EA (1) EA003128B1 (ko)
HK (1) HK1025737A1 (ko)
HU (1) HU226612B1 (ko)
IL (2) IL119989A0 (ko)
NZ (1) NZ336690A (ko)
PL (1) PL193300B1 (ko)
SK (1) SK284029B6 (ko)
WO (1) WO1998030227A1 (ko)
ZA (1) ZA98214B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2337688C (en) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005249A2 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1187612B1 (en) * 1999-06-04 2005-01-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
DE60120648D1 (de) * 2000-02-18 2006-07-27 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0302333A3 (en) * 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO2003048735A2 (en) 2001-12-04 2003-06-12 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
SI2336184T1 (sl) 2002-02-25 2015-04-30 Biogen Idec Ma Inc. Dajanje sredstev za zdravljenje vnetij
CA2514125A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
US7560100B2 (en) 2004-09-09 2009-07-14 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
CZ30474U1 (cs) 2009-08-20 2017-03-14 Yeda Research And Development Co., Ltd. Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽(glatiramer acetate)之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US10330650B2 (en) * 2015-04-28 2019-06-25 Hybio Pharmaceutical Co., Ltd. High performance liquid chromatography method for polypeptide mixtures
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
EP3645029B1 (en) 2017-06-26 2023-01-18 Institut Pasteur Treatments to eliminate hiv reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
ATE356608T1 (de) 2007-04-15
HK1025737A1 (en) 2000-11-24
JP2001511121A (ja) 2001-08-07
AU5819598A (en) 1998-08-03
WO1998030227A1 (en) 1998-07-16
NZ336690A (en) 2001-05-25
CN1249690A (zh) 2000-04-05
EP0975351A1 (en) 2000-02-02
EA003128B1 (ru) 2003-02-27
CN100528222C (zh) 2009-08-19
PL193300B1 (pl) 2007-01-31
EP0975351A4 (en) 2002-05-15
CA2277365C (en) 2011-04-12
EP0975351B1 (en) 2007-03-14
IL119989A0 (en) 1997-04-15
KR20000070058A (ko) 2000-11-25
CA2277365A1 (en) 1998-07-16
BRPI9807076B8 (pt) 2021-05-25
ZA98214B (en) 1999-08-11
AU737287B2 (en) 2001-08-16
HUP0001917A3 (en) 2001-12-28
DE69837324T2 (de) 2007-11-29
HUP0001917A2 (hu) 2000-10-28
BR9807076B1 (pt) 2013-10-29
PL334566A1 (en) 2000-03-13
EA199900621A1 (ru) 2000-02-28
IL130820A (en) 2007-03-08
BR9807076A (pt) 2000-05-02
CZ297983B6 (cs) 2007-05-16
JP4216342B2 (ja) 2009-01-28
DE69837324D1 (de) 2007-04-26
HU226612B1 (en) 2009-04-28
CZ243799A3 (cs) 2000-06-14
SK93199A3 (en) 2000-11-07

Similar Documents

Publication Publication Date Title
SK284029B6 (sk) Farmaceutická kompozícia na liečenie roztrúsenej sklerózy
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
AU742970B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
CN106668852B (zh) 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
JP2527749B2 (ja) 移植拒否反応抑制または自己免疫疾患治療用薬学的組成物
EP2523668A1 (en) Treatment of multiple sclerosis
EP2046366B1 (en) Copolymer-1 for treatment of age-related macular degeneration
AU2003250892A1 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
RU2647438C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
HUT74900A (en) Treatment of autoimmune disease using oral tolerization and/or type i interferon
Hayashi et al. Protective role of nitric oxide in ocular toxoplasmosis.
KR100435040B1 (ko) 티세포매개성질환들의치료를위한제제들및방법들
Sela Immunomodulatory vaccines against autoimmune diseases
US8349314B2 (en) Method of treating and/or preventing type II diabetes using Actinomycetales
EP4353234A1 (en) Use of pyrrolopyrimidine compound
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
US20240238299A1 (en) Use of pyrrolopyrimidine compound
WO2023037160A2 (ru) Набор и разовая дозированная форма для профилактики сахарного диабета 1 типа, их применение для профилактики сахарного диабета 1 типа. способ профилактики сахарного диабета 1 типа у здоровых людей из группы высокого риска

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180112